Jing X Liu

20100323393, Dec 23, 2010

Jun 22, 2010

12/820933

Xiuli An - Bayside NY, US
Mohandas Narla - New York NY, US
Jing Liu - Woodside NY, US
Susanne Heck - Bronx NY, US

C12Q 1/06
C12N 5/078
C12Q 1/02
C12Q 1/04

435 39, 435325, 435 29, 435 34

Disclosed herein are methods for the isolation, identification, and quantification of red blood cells and red blood cell precursors at different developmental stages. Also disclosed are methods for monitoring ex vivo proliferation and differentiation of red blood cells and red blood cell progenitors.

20120295285, Nov 22, 2012

Jul 13, 2012

13/548761

Xiuli An - Bayside NY, US
Mohandas Narla - New York NY, US
Jing Liu - Woodside NY, US
Susanne Heck - Bronx NY, US

NEW YORK BLOOD CENTER, INC. - New York NY

C12Q 1/04
G01N 21/64
G01N 33/566
C12Q 1/06

435 725, 435 34, 435 39

Disclosed herein are methods for the isolation, identification, and quantification of red blood cells and red blood cell precursors at different developmental stages. Also disclosed are methods for monitoring ex vivo proliferation and differentiation of red blood cells and red blood cell progenitors.

20130017250, Jan 17, 2013

Jul 16, 2012

13/550567

Henry Ginsberg - Dobbs Ferry NY, US
Jing Liu - New York NY, US

The Trustees of Columbia University in the City of New York - New York City NY

A61K 38/44
G01N 21/76
A61P 3/10
C07H 21/04
A61K 9/127
A61P 9/00
G01N 21/17
G01N 21/64

424450, 435 29, 435 8, 424 944, 536 241

It was discovered that insulin binding to insulin receptors signals the upregulation of expression of the liver enzyme deiodinase 1 (Dio1), which in turn activates the ApoA-1 promoter, thereby thereby increasing ApoA-1 expression (primarily in the liver), that in turn raises the levels of plasma ApoA-1, the major and necessary protein in HDLC. Certain embodiments of the invention are directed to methods for increasing circulating HDLC levels in an animal by administering therapeutically effective amounts of Dio1, or by increasing the level of Dio1 through gene therapy.

20220348580, Nov 3, 2022

Jun 21, 2019

17/254345

- New York NY, US
- Chapel Hill NC, US
Jing Liu - New York NY, US
Xufen Yu - New York NY, US
Dongxu Li - Chapel Hill NC, US

C07D 487/04
C07D 401/14
C07D 417/14

Disclosed herein are WD40 repeat domain protein 5 (WDR5) degradation/disruption compounds including a WDR5 ligand, a degradation/disruption tag, and a linker, and methods of using such compounds in the treatment of WDR5-mediated diseases.

20220288207, Sep 15, 2022

Jul 24, 2020

17/629707

- Boston MA, US
- New York NY, US
Husnu Umit KANISKAN - New York NY, US
He CHEN - New York NY, US
Jing LIU - Boston MA, US

Beth Israel Deaconess Medical Center, Inc. - Boston MA
Icahn School of Medicine at Mount Sinai - New York NY

A61K 41/00
A61K 47/55
A61K 47/54
A61P 35/00

By hijacking endogenous E3 ligase to degrade protein targets via the ubiquitin-proteasome system, PROTACs (PRoteolysis TArgeting Chimeras) provide a new strategy to inhibit protein targets that were previously regarded as undruggable. The compounds described herein comprise a photolabile group on PROTACs, enabling the degradation of protein targets in a spatiotemporally controlled manner By adding a photolabile caging group on ubiquitin recruiting moieties, light-inducible protein degradation was acheived. These opto-PROTACs display no activity in the dark, while restricted degradation can be induced at a specific time and rate by UVA-irradiation. Accordingly, these compounds provide light-controlled PROTACs and methods of using such compounds.

20230070613, Mar 9, 2023

Jul 3, 2019

17/256516

- New York NY, US
Hanna Irie - New York NY, US
Jing Liu - New York NY, US
Yan Xiong - New York NY, US
Jessica Byerly - New York NY, US
Shannon Tomita - New York NY, US
Jianping Hu - New York NY, US

A61K 47/54
A61P 35/00
A61K 45/06

Disclosed herein are protein tyrosine kinase 6 (PTK6) degradation/disruption compounds including a PTK6 ligand, a N degradation/disruption tag, and a linker, and methods of using such compounds in the treatment of FTK6-mediated diseases.

20210395244, Dec 23, 2021

Jun 1, 2021

17/336059

- New York NY, US
Jing Liu - New York NY, US
Jianping Hu - New York NY, US
Jieli Wei - Kunming, CN
Hyerin Yim - New York NY, US
Md Kabir - New York NY, US

C07D 417/12
A61K 9/00
A61P 35/00

This disclosure relates to heterobifunctional compounds (e.g., bi-functional small molecule compounds), compositions comprising one or more of the heterobifunctional compounds, and to methods of use the heterobifunctional compounds for the treatment of certain disease in a subject in need thereof. The disclosure also relates to methods for identifying such heterobifunctional compounds.

20210283261, Sep 16, 2021

Dec 4, 2018

16/769326

- New york NY, US
- Chapel Hill NC, US
Jing Liu - New York NY, US
Chengwei Zhang - New York NY, US
Xiaoran Han - Chapel Hill NC, US
He Chen - New York NY, US
Pu Wang - Chapel Hill NC, US

A61K 47/54
A61K 31/506
C07D 401/14
C07D 417/14
G01N 33/50

Heterobifunctional small molecules including anaplastic lymphoma kinase (ALK) ligand conjugated to a degradation/disruption tag through a linker, which selectively degrade/disrupt ALK, ALK fusion proteins, and/or ALK mutant proteins, and compositions and methods of using such degraders/disruptors to treat ALK-mediated cancer are provided.